نتائج البحث
نتائج البحث
A PHASE III, MULTICENTER, RANDOMISED, DOUBLEBLIND, PLACEBOCONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER قائمة الدراسات السريرية المسجلة على الادوية
A Phase III, Multicenter, Randomized, parallel-group study to asses the efficacy and saftey of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open lable octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly. قائمة الدراسات السريرية المسجلة على الادوية